《大行報告》野村降藥明生物(02269.HK)目標價至53.65元 下調盈測
野村發表研究報告指,維持藥明生物(02269.HK)「買入」評級,目標價由58.44元下調至53.65元。由於估值吸引,技術上對其看法正面。另外,考慮到由於競爭激烈導致潛在均價下跌,該行分別下調2023及24財年的收入預測1.3%和4.2%。
該行又調低藥明生物毛利率及營運利潤率預測,因為其新生產設施或會在啟動階段出現較低的利潤率和較高的營運開支。該行考慮到由於中國生物科技板塊估值下降而導致投資收益可能減少,下調集團2023年下半年和2024財年的其他收入預測。因此,2023及24財年的盈利預測分別下調14.2%及14.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.